Shares of Macrogenics MGNX were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 27.47% over the past year to ($0.66), which beat the estimate of ($0.93).
Revenue of $18,253,000 declined by 2.60% from the same period last year, which beat the estimate of $15,790,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Nov 04, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/winmrboe
Price Action
52-week high: $32.18
Company's 52-week low was at $4.04
Price action over last quarter: down 17.09%
Company Profile
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
